Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy-Reference-Cited by-同舟云学术

Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy

Published:2021-01-26 Issue:11 Volume:25 Page:2859-2870
ISSN:1091-255X
Container-title:Journal of Gastrointestinal Surgery
language:en
Short-container-title:J Gastrointest Surg

Author:

Michelakos Theodoros,Sekigami Yurie,Kontos Filippos,Fernández-del Castillo Carlos,Qadan Motaz,Deshpande Vikram,Ting David T.,Clark Jeffrey W.,Weekes Colin D.,Parikh Aparna,Ryan David P.,Wo Jennifer Y.,Hong Theodore S.,Allen Jill N.,Catalano Onofrio,Warshaw Andrew L.,Lillemoe Keith D.,Ferrone Cristina R.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,Surgery

Link

https://link.springer.com/content/pdf/10.1007/s11605-020-04897-9.pdf

Reference23 articles.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30. doi:https://doi.org/10.3322/caac.21590.

2. Michelakos T, Ferrone CR. Neoadjuvant chemotherapy in pancreatic cancer. In: Neoptolemos JP, Urrutia R, Abbruzzese JL, Büchler MW, editors. Pancreatic Cancer. New York, NY: Springer New York; 2018. p. 1187-1202.

3. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M, Groupe Tumeurs Digestives of U, Intergroup P. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817-1825. doi:https://doi.org/10.1056/NEJMoa1011923.

4. Michelakos T, Xourafas D, Qadan M, Pieretti-Vanmarcke R, Cai L, Patel MS, Adler JT, Fontan F, Basit U, Vagefi PA, Elias N, Tanabe KK, Berger D, Yeh H, Markmann JF, Chang DC, Ferrone CR. Hepatocellular carcinoma in transplantable Child-Pugh A cirrhotics: should cost affect resection vs transplantation? J Gastrointest Surg. 2019;23(6):1135-1142. doi:https://doi.org/10.1007/s11605-018-3946-z.

5. Murphy JE, Wo JY, Ryan DP, Jiang W, Yeap BY, Drapek LC, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Faris JE, Zhu AX, Goyal L, Lillemoe KD, DeLaney TF, Fernandez-Del Castillo C, Ferrone CR, Hong TS. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2018;4(7):963-969. doi:https://doi.org/10.1001/jamaoncol.2018.0329.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Significance of Biologic Factors in Patients with a Modest Radiologic Response to Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancers: Impact of the Combination Index of Sialyl-Lewis Antigen-Related Tumor Markers;Annals of Surgical Oncology;2024-02-17

2. Conditional Relative Survival of Exocrine Pancreatic Cancer: A Population-Based Study;Annals of Surgical Oncology;2023-11-30

3. Total neoadjuvant therapy improves survival of patients with borderline resectable pancreatic cancer with arterial involvement;Annals of Gastroenterological Surgery;2023-08-10

4. Profile of the Postoperative Care Provided for Patients With Pancreatic and Periampullary Cancers by Family and Unpaid Caregivers;JCO Oncology Practice;2023-08

5. Pathological Nodal and Vascular Involvement Significantly Impacts the Recurrence Risk in Different Time Frames in Patients With Resectable and Borderline Resectable Pancreatic Cancer;Annals of Surgery;2023-04-14